Delivery Order SPE2DB22D9130-SPE2DB25FE0DD

Award Date 3/19/25
Potential Completion Date 4/9/25
Potential Value $8.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $8,220.68, is for the delivery of 4567503104 - STELARA 90 MG/ML SYRINGEML, a specialized prescription medication, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $8,220.68 contract is for the delivery of STELARA 90 MG/ML SYRINGE with a period of performance through March 20, 2025. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $6,992.70 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract is for the supply of STELARA 90 MG/ML SYRINGE, a biologic medication, with an ultimate completion date of March 28, 2024. This delivery order is issued under DMS Pharmaceutical Group's larger indefinite delivery contract with DLA, valued up to $4,999,999, that enables the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $16,441.36, is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $8,220.68, is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. The contract has an ultimate completion date of April 7, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,220.68 contract is for the supply of STELARA 90 MG/ML SYRINGE/ML, a specialized pharmaceutical product. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC enables the DLA to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $49,324.08, is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. The contract is not associated with any set-aside designation, allowing DMS...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $7,795.18 contract is for the delivery of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, with a completion date of November 14, 2024. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,220.68 contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical needs of military healthcare facilities. The award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $16,441.36 firm fixed-price contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue delivery orders for a comprehensive range of branded...
  • SPE2DB22D9130
    Indefinite Delivery Contract
  • SPE2DB22D9130-SPE2DB25FE0DD
    Delivery Order

This is a $8,220.68 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the provision of STELARA 90 MG/ML SYRINGEML, a specialized pharmaceutical product, to support the medical supply needs of military health facilities. The contract has an ultimate completion date of April 9, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. also holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This positions DMS Pharmaceutical Group as a crucial supplier in the federal pharmaceutical supply chain, providing direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.

Generated 6/18/25, 10:45 AM